Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and newly diagnosed with advanced stage 3 or 4 ovarian, fallopian tube, or primary peritoneal cancer.
- You must have a BRCA1 or BRCA2 gene mutation confirmed by genetic testing.
- Your cancer must be the high-grade serous type or a similar aggressive type, and it cannot be fully removed with surgery at this time.
- You must have at least one tumor that can be seen on a CT or MRI scan.
- You must be in generally good health with adequate organ function (kidneys, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests two investigational drug combinations (fluzoparib plus famitinib, or fluzoparib plus SHR-1701) given before surgery to shrink ovarian cancer. The goal is to see which approach helps more with tumor reduction and making surgery more effective.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.